Tumor-LN-oC completes selection of materials and processesMarch 25, 2022
With the conclusion of Month 10 of the project, the Tumor-LN-oC consortium successfully passed the second milestone of the project: the final selection of specifications for materials, processes and user requirements.
In the past few months, the team has been working hard to test and specify the selection of processes and materials, in particular cells, tissues, and growth media for the Tumor-LN-oC Platform. These specifications were further verified by end-users of the Organ-on-Chip device in a public questionnaire.
The Tumor-LN-oC platform in development will make it possible to monitor complex processes such as tissue crosstalk and metastasis and will serve as a platform for parallel preclinical testing of drugs for individual patients aiming at precision medicine approaches. Please get in touch with us and stay updated on our Twitter and LinkedIn pages to learn more about the project.
In the meantime, the end-user questionnaire, targeted towards clinicians, researchers and pharmaceutical representatives interested in metastasis diagnosis and monitoring will remain open for submission throughout the project and the consortium is grateful is about any further input. Please visit the form here. Thank you for your participation!